Jefferies Financial Group Inc. Buys Shares of 2,134 Axon Enterprise, Inc $AXON

Jefferies Financial Group Inc. purchased a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,134 shares of the biotechnology company’s stock, valued at approximately $1,196,000.

Several other hedge funds have also made changes to their positions in the business. Rockefeller Capital Management L.P. raised its holdings in shares of Axon Enterprise by 53.2% in the 4th quarter. Rockefeller Capital Management L.P. now owns 11,518 shares of the biotechnology company’s stock valued at $6,542,000 after purchasing an additional 4,002 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Axon Enterprise by 1.3% during the fourth quarter. Legal & General Group Plc now owns 426,533 shares of the biotechnology company’s stock worth $242,241,000 after purchasing an additional 5,419 shares in the last quarter. Eurizon Capital SGR S.p.A. purchased a new position in Axon Enterprise in the fourth quarter valued at $13,116,000. B. Metzler seel. Sohn & Co. AG purchased a new position in Axon Enterprise in the second quarter valued at $3,854,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in Axon Enterprise in the first quarter valued at $15,067,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Insiders Place Their Bets

In other news, CRO Cameron Brooks sold 1,242 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $500.00, for a total value of $621,000.00. Following the completion of the sale, the executive directly owned 49,710 shares of the company’s stock, valued at approximately $24,855,000. This represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $485.00, for a total transaction of $753,690.00. Following the transaction, the insider owned 34,024 shares in the company, valued at approximately $16,501,640. This trade represents a 4.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 75,401 shares of company stock valued at $40,670,843. 4.20% of the stock is owned by insiders.

Axon Enterprise Price Performance

AXON opened at $600.73 on Monday. Axon Enterprise, Inc has a one year low of $339.01 and a one year high of $792.16. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.80 and a current ratio of 2.15. The stock has a market capitalization of $48.80 billion, a P/E ratio of 249.27, a price-to-earnings-growth ratio of 9.75 and a beta of 1.39. The business’s 50-day simple moving average is $560.75 and its 200-day simple moving average is $483.34.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.84 by $0.04. The firm had revenue of $904.39 million during the quarter, compared to analysts’ expectations of $876.42 million. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The business’s revenue was up 35.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.12 EPS. Analysts anticipate that Axon Enterprise, Inc will post 2.04 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on AXON shares. Barclays upped their price objective on Axon Enterprise from $523.00 to $688.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. UBS Group raised their target price on Axon Enterprise from $440.00 to $600.00 and gave the stock a “neutral” rating in a research report on Thursday, August 6th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $700.00 price target on shares of Axon Enterprise in a report on Thursday, June 25th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $715.00 price target on shares of Axon Enterprise in a report on Thursday, August 6th. Finally, Morgan Stanley raised their price objective on shares of Axon Enterprise from $600.00 to $640.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Thirteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $730.92.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.